New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
11:05 EDTCI, AZNCigna, AstraZeneca in Crestor pact
Cigna (CI) has entered into a first-of-its-kind contract with AstraZeneca (AZN) to help ensure that customers are given an appropriate cholesterol-lowering medication based on their treatment needs. For Cigna customers who are at increased risk for atherosclerotic cardiovascular disease, ASCVD, and need to aggressively manage their low-density lipoprotein cholesterol, LDL-C, CRESTOR , a brand-name, cholesterol-lowering drug manufactured by AstraZeneca, can be prescribed and filled without requiring prior authorization. “Our arrangement with Cigna is an evolutionary step in supporting patient health, and facilitating access to CRESTOR for high risk patients. Predictive risk modeling can be used to help support the right treatment for the right patient at the right time, and we are excited to be working with Cigna because they are the only insurance carrier or Pharmacy Benefit Manager we have seen who has offered this capability,” says Philip de Vane, MD, Executive Director of US Medical Affairs, AstraZeneca.
News For AZN;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
09:10 EDTAZNPharmacyclics initiates cancer study of ibrutinib with AstraZeneca's MEDI4736
Pharmacyclics (PCYC) initiated PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib in combination with MEDI4736, an investigational, anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca (AZN). The Phase Ib/II study will examine the safety, tolerability and effectiveness of this investigational combination in individuals with relapsed or refractory non-small cell lung cancer, breast cancer, and pancreatic cancer. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
07:14 EDTAZNMyriad Genetics, AstraZeneca expand research collaboration on Lynparza
Subscribe for More Information
March 31, 2015
09:03 EDTAZNAstraZeneca says Movantik has launched in the U.S.
Subscribe for More Information
March 30, 2015
09:29 EDTCICatamaran buyout a 'significant positive' for holders, says Leerink
Leerink views the buyout by UnitedHealth (UNH) as a "significant positive" for the shareholders of Catamaran (CTRX). The firm does not expect additional bidders to emerge. It also believes Catamaran will retain Cigna (CI) and HealthSpring as a client given the long-term nature of the contract and Catamaran's expertise in Medicare.
09:01 EDTAZNAstraZeneca says FDA approves new administration option for Brilinta
AstraZeneca announced that the US FDA has approved a new administration option for acute coronary syndrome patients who are unable to swallow BRILINTA 90 mg tablets whole. Unlike other P2Y12 inhibitors, BRILINTA has FDA approval to be crushed and administered in water by swallowing or via nasogastric tube.
07:48 EDTAZNAcquisition of BioMarin would make sense for several companies, says SunTrust
Subscribe for More Information
March 26, 2015
11:13 EDTAZNBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 25, 2015
07:38 EDTCIPrice targets raised for Managed Care Organizations at UBS
UBS raised its price targets on the Managed Care Organizations in their coverage universe. The firm cites increased volumes, a lack of new legislation, the potential for industry consolidation, and limited exposure to international markets that face a weak macro economic backdrop. UBS raised its price target on Aetna (AET) to $128 from $120, Anthem (ANTM) to $175 from $163, Cigna (CI) to $149 from $140 and United Health (UNH) to $135 from $131. UBS has a Buy rating on all four stocks.
March 23, 2015
09:45 EDTAZNUBS to hold a field trip
Subscribe for More Information
09:06 EDTAZNInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
09:03 EDTAZNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:36 EDTAZNPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
08:18 EDTCILeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
07:55 EDTAZNAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
March 19, 2015
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use